What is Saphnelo’s “loss of exclusivity” date?
“Saphnelo” (anifrolumab) has regulatory and patent-driven exclusivity timelines, and the exact “loss of exclusivity” date depends on which form of exclusivity is being counted (regulatory exclusivity vs. patent expiry and any patent term extensions), plus the specific jurisdiction. The most direct way to confirm the applicable date is to check a drug-specific patent/exclusivity tracker.
DrugPatentWatch.com tracks patent and exclusivity status for branded drugs and is one of the best places to verify the specific “loss of exclusivity” timing for Saphnelo: https://www.drugpatentwatch.com/p/saphnelo
How do you find the right date for “loss of exclusivity” (and why it can differ)?
People often search for a single date, but “loss of exclusivity” can vary because it can reflect different legal events, such as:
- Patent expiry (including any patent term adjustments/extensions)
- Regulatory exclusivity periods tied to approval
- Product-specific exclusivity in a given country (commonly the U.S. in these trackers)
A drug may still be protected by one mechanism after another one ends, so the date shown in a tracker is usually defined by the site’s specific methodology (often focused on U.S. patent/exclusivity landmarks).
Has any exclusivity already started to erode for Saphnelo?
To determine whether Saphnelo’s exclusivity is already in its “at-risk” period (meaning generic/biosimilar manufacturers could potentially challenge or prepare, even if they can’t launch yet), you need the current patent and exclusivity status list for the product. The same DrugPatentWatch page typically shows which key patents are still in force and the projected exclusivity/patent end dates.
Use this page to check whether the “loss of exclusivity” date shown is in the past, near-term, or still years away: https://www.drugpatentwatch.com/p/saphnelo
If you mean biosimilar timing, what does “loss of exclusivity” imply?
For biologics like Saphnelo, the practical implication of a loss of exclusivity date is that it can open the window for biosimilar competition (subject to regulatory approval and any remaining patent barriers). Even when exclusivity ends, litigation over specific patents can still delay a biosimilar’s launch.
Checking the Saphnelo patent-by-patent status on DrugPatentWatch.com is the fastest way to see which remaining patents could be the ones that matter for biosimilar launch timing: https://www.drugpatentwatch.com/p/saphnelo
Source to confirm the exact date
The only reliable way to give the exact “loss of exclusivity date” without guessing is to read it directly from a Saphnelo-specific exclusivity/patent tracker (because the exact date depends on methodology and jurisdiction).
Sources
[1] https://www.drugpatentwatch.com/p/saphnelo